



Half Year Results Presentation

29 November 2023



Unichem⁺

life
Pharmacy

PillDrop[®]
Pharmacy. Your Way.

+ the doctors

+ HouseCall

 **GREEN
CROSS**
HEALTH

respectful 尊重的
manaaki tangata responsible
关心 mōhio ki te mahi compassionate
efficient 高效的
empathetic 同情同理的 welcome

Disclaimer

The information in this presentation was prepared by Green Cross Health Limited (GXH) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliability of the information. In addition, neither GXH nor any of its subsidiaries, directors, employees, shareholders nor any other person shall have liability whatsoever to any person for any loss (including, without limitation, arising from any fault or negligence) arising from this presentation or any information supplied in connection with it.

This presentation may contain forward-looking statements and projections. These reflect GXH current expectations, based on what it thinks are reasonable assumptions. GXH gives no warranty or representation as to its future financial performance or any future matter. Except as required by law or NZX listing rules, GXH is not obliged to update this presentation after its release, even if things change materially. This presentation does not constitute financial advice. Further, this presentation is not and should not be construed as an offer to sell or a solicitation of an offer to buy GXH securities and may not be relied upon in connection with any purchase of GXH securities.

This presentation contains a number of non-GAAP financial measures, including Operating Revenue and Operating Profit (EBIT). As they are not defined by GAAP or IFRS, GXH calculation of these measures may differ from similarly titled measures presented by other companies and they should not be considered in isolation from, or construed as an alternative to, other financial measures determined in accordance with GAAP. Although GXH believes they provide useful information in measuring the financial performance and condition of GXH business, readers are cautioned not to place undue reliance on these non-GAAP financial measures.

The information contained in this presentation should be considered in conjunction with the consolidated financial statements for the six months ended 30 September 2023.

Operational Highlights

Group Highlights

- \$2.2m increase in Group Revenue year-on-year
- Significant investment in IT infrastructure; ERP upgrade completed and product information system replaced

Pharmacy Division

- Total prescriptions up 3.3% on same-store basis
- \$5 co-payment removal
- 295,961 flu vaccinations administered
- Five store refurbishments

Medical Division

- 399,000 enrolled patients (+16% YOY)
- Acquisition of three new medical centres
- Three centre refurbishments
- Successful rollout of practice management system upgrade to further 25 medical centres

GXH Interim Result - Financial Overview

Group Performance

Group Revenue



\$250.2m

▲ 1% increase vs 1H23

Operating Profit (EBIT)



\$14.9m

▼ 17% decrease vs 1H23

Net Profit After Tax (attributable to shareholders)



\$5.6m

▼ 21% decrease vs 1H23*

*Comparative (FY23 H1) of \$7.1m excludes profit from discontinued operation of \$4.3m.

Divisional Performance

Pharmacy Operating Profit (EBIT)



\$8.7m

▼ 25% decrease vs 1H23

Medical Operating Profit (EBIT)



\$7.3m

▼ 21% decrease vs 1H23




Pharmacy Division



New Zealand's largest network of health retailers: supporting easy access to quality health care

Pharmacy Performance

Pharmacy Revenue (\$m)



Pharmacy Operating Profit/EBIT (\$m)



Unichem⁺

life
Pharmacy

PillDrop
Pharmacy. Your Way.

- + Revenue of \$182m
- + Operating Profit (EBIT) at \$8.7m
- + Diminished levels of higher-margin COVID-19 activity and increased labour costs resulted in **Operating Profit (EBIT)** down 25%
- + Same store direct labour costs up 11% given shortages and inflationary pressures, with **initiatives underway to reduce costs** and increase operational efficiency
- + **\$5 co-payment removal** bolstered dispensary sales


Operational Highlights - Pharmacy

- ⊕ Continued growth in influenza vaccination volumes, up 3.3% on 1H23
- ⊕ Initial scripts up 5.9% vs. 1H23 for same stores
- ⊕ Increase in loyalty membership to 1.99m members
- ⊕ Living Rewards members spend 60% more than non-members




1,990,840 Living Rewards members

Flu Vaccines and Total Scripts



Pharmacy Will Win By Focusing on the Customer





Medical Division


 the**doctors**  House**Call**

Growth, leadership and sustainable models of care




Medical Performance






Medical Revenue (\$m)







Medical Operating Profit/EBIT (\$m)



 thedoctors  HouseCall

-  Revenue up 1% to \$69m
-  Diminished levels of COVID-19 activity and increased labour costs resulted in **Operating Profit (EBIT) down 21% to \$7.3m**
-  **Review of cost base** to minimise impact of labour shortages and inflationary pressure
-  **399,000 enrolled patients** as at 30 September 2023, an increase of 54,000 (+16%) since 30 September 2022
-  **Ownership** in 63 medical centres


Operational Highlights - Medical

-  Successful completion of three acquisitions to end period with 63 medical centres. Two further acquisitions completed post Sep-23
-  Strong pipeline of future acquisitions
-  HouseCall virtual care service can now be accessed via The Doctors App
-  The Doctors has New Zealand's largest general practice enrolled patient base


 thedoctors

399,000 enrolled patients


The Doctors App



Enrolled Patients ('000)



Medical Strategy of Organic Growth & Acquisitions








Group Financial Result

6 months ending 30 September 2023


Group Revenue and Operating Profit (EBIT)



Revenue From Continuing Operations (\$m)



-  Revenue of \$250m, up 1% vs 1H23
-  Fourth consecutive year of revenue growth


Operating Profit (EBIT) From Continuing Operations (\$m)




-  Operating Profit (EBIT) from continuing operations of \$14.9m, down 17%
-  1H24 Operating Profit (EBIT) decline is the result of reduced COVID-19 activity, a challenging retail environment and increased labour costs




Group NPAT, EPS & Dividend

Net Profit After Tax Attributable to Shareholders From Continuing Operations (\$m)




Net Profit After Tax Attributable to Shareholders From Continuing Operations (cps)






-  Net Profit After Tax Attributable to Shareholders down 21% on a continuing operations basis
-  EPS at 3.91 cps, a decrease of 1 cent
-  Interim dividend of 2.5 cps (\$3.6m) declared, to be paid on 20 December 2023


Working Capital and Operating Cash Flow

Gearing Ratio (debt / debt + equity)





-  Gearing ratio of 16.2% as at 30 September 2023
-  Robust working capital management ensures GXH maintains a strong balance sheet to support its strategy of acquisitive growth
-  Financing ratios (pre IFRS16):
 - Debt / EBITDA – 1.0x
 - Operating Profit (EBIT) / Interest – 10x

GXH Operating Cash Flow (\$m)








-  Operating Cash Flow of \$18.8m

Enabling investment (\$7.9m) in:

-  Three medical centre acquisitions
-  Ongoing site capex requirements including five Pharmacy refurbishments and three Medical refurbishments

Outlook

-  Challenging retail environment, labour cost pressures and funding shortfalls continue in short-term
-  Maximising labour efficiency and management of costs a priority
-  Focus remains on sustained earnings growth through acquisition and investment in new product and service offerings
-  Earnings over the remainder of the year are expected to track more in line with the second half of the prior financial year on a continuing operations basis
-  Dividend of 2.5cps declared for the half-year ended 30 September 2023



About Green Cross Health



Our Purpose

Working together to support healthier communities.

We are passionately committed to the health and wellness of New Zealand, and to providing the best support, care and advice to our communities.

This is our promise.



Who We Are

Pharmacies providing extensive range of health, wellness and beauty related products and services across communities throughout New Zealand, supported by digital offerings.

338
pharmacies

55
life Pharmacy

283
Unichem⁺



1.99 million
loyalty members



-  Unichem Pharmacies
-  Life Pharmacies
-  The Doctors Medical Centres

63
medical centres

 the **doctors**

 HouseCall

399,000
enrolled patients


439
nurses


451
doctors


25
nurse practitioners

General practice networks across New Zealand, offering in-practice and virtual services.

As at September 2023